SBIR/STTR Research Award

Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate

Award identifier 8595d907281be24897913d75f4e4832446fa0a7e04e278241660be2b9a288a6eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$238,130

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NeuroFx, Inc.
Proposal award date
2018-09-20
Contract end date
2019-08-31
UEI
KY9XKL5CRLP8
Solicitation number
PA17-303
Topic code
300

Research abstract

ABSTRACT Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of incidence of AKIno therapy currently existsother than supportive careAlsoAKI occurs in up toof all patients undergoing cardiac surgeryDespite advances in bypass techniques and intensive caremortality and morbidity associated with AKI have not changed in the last decadeFurthermoreAKI represents a potential link to chronic kidney diseaseMesenchymal stem cellMSCtherapies have shown promise in renal disease modelshoweverthere are logistical barriers and potential safety concerns which will limit the usefulness of this therapyWe and others have shown the therapeutic potential of MSC secretome in ischemia reperfusionacutekidney injury modelsHerewe propose to assess the therapeutic effect of NFxour lead therapeutic agentin the rat kidney ischemia reperfusion injury model when infused beforeimmediately afterorhours post injury as well as to evaluate the therapeutic effect of NFxto prevent development of chronic kidney injury in a rat model of high salt induced kidney failureAs a result of this Phase I study we will establish the optimal NFxdose and regiment of treatmentwhich then will be used for Phase II study NARRATIVE Acute kidney injurya syndrome characterized by the rapid loss of the kidneyandapos s excretory functionis the leading cause of nephrology consultationandmillion hospital admissions a yearresulting in health care costs of $billionand one of the major causes of development of chronic kidney diseaseUnfortunatelyAKI specific interventions beyond supportive therapy are currently not availableWe propose to develop a therapy based on therapeutic factors produced by stem cells that could potentially benefit the patients with acute kidney injury by reducing the damage of the functional tissue and vasculature of the kidneys

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2015–2019). Reported award amounts total $741,434. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.